[go: up one dir, main page]

Howard et al., 2018 - Google Patents

Dose adjustment in orphan disease populations: the quest to fulfill the requirements of physiologically based pharmacokinetics

Howard et al., 2018

Document ID
18039808665408078131
Author
Howard M
Barber J
Alizai N
Rostami-Hodjegan A
Publication year
Publication venue
Expert Opinion on Drug Metabolism & Toxicology

External Links

Snippet

Introduction: While the media is engaged and fascinated by the idea of 'Precision Medicine', the nuances related to 'Precision Dosing'seem to be largely ignored. Assuming the 'right drug'is selected, clinicians still need to decide on the 'right dose'for individuals. Ideally …
Continue reading at www.tandfonline.com (other versions)

Classifications

    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
    • G06F19/3456—Computer-assisted prescription or delivery of medication, e.g. prescription filling or compliance checking
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
    • G06F19/3437—Medical simulation or modelling, e.g. simulating the evolution of medical disorders
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
    • G06F19/3475—Computer-assisted prescription or delivery of diets, e.g. prescription filling or compliance checking
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
    • G06F19/322—Management of patient personal data, e.g. patient records, conversion of records or privacy aspects
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/36—Computer-assisted acquisition of medical data, e.g. computerised clinical trials or questionnaires
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
    • G06F19/18—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
    • G06F19/28—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for programming tools or database systems, e.g. ontologies, heterogeneous data integration, data warehousing or computing architectures
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/10—Services
    • G06Q50/22—Health care, e.g. hospitals; Social work
    • G06Q50/24—Patient record management
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/70—Chemoinformatics, i.e. data processing methods or systems for the retrieval, analysis, visualisation, or storage of physicochemical or structural data of chemical compounds
    • G06F19/706—Chemoinformatics, i.e. data processing methods or systems for the retrieval, analysis, visualisation, or storage of physicochemical or structural data of chemical compounds for drug design with the emphasis on a therapeutic agent, e.g. ligand-biological target interactions, pharmacophore generation
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
    • G06F17/20—Handling natural language data

Similar Documents

Publication Publication Date Title
Jiang et al. Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children
Yoshida et al. In vitro–in vivo extrapolation of metabolism-and transporter-mediated drug–drug interactions—overview of basic prediction methods
Howard et al. Dose adjustment in orphan disease populations: the quest to fulfill the requirements of physiologically based pharmacokinetics
Abouir et al. Reviewing data integrated for PBPK model development to predict metabolic drug-drug interactions: shifting perspectives and emerging trends
Lesko et al. Individualization of drug therapy: history, present state, and opportunities for the future
Roerig et al. A comparison of duloxetine plasma levels in postbariatric surgery patients versus matched nonsurgical control subjects
Salem et al. Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug–drug interactions
Türk et al. Physiologically based pharmacokinetic models for prediction of complex CYP2C8 and OATP1B1 (SLCO1B1) drug–drug–gene interactions: a modeling network of gemfibrozil, repaglinide, pioglitazone, rifampicin, clarithromycin and itraconazole
Tamaki et al. Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
Samji et al. Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development
George et al. NAFLD: The evolving landscape
Lammers et al. The effects of fasting on drug metabolism
Alqahtani et al. An update on the potential role of intestinal first-pass metabolism for the prediction of drug–drug interactions: The role of PBPK modeling
Job et al. Development of a generic physiologically‐based pharmacokinetic model for lactation and prediction of maternal and infant exposure to ondansetron via breast milk
Chung et al. Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: a Mendelian randomization and population-based cohort study
Hjelmesæth et al. Impact of body weight, low energy diet and gastric bypass on drug bioavailability, cardiovascular risk factors and metabolic biomarkers: protocol for an open, non-randomised, three-armed single centre study (COCKTAIL)
Jetten et al. Interindividual variation in gene expression responses and metabolite formation in acetaminophen-exposed primary human hepatocytes
Marques et al. Prediction of CYP-mediated drug interaction using physiologically based pharmacokinetic modeling: a case study of salbutamol and fluvoxamine
Ozdemir et al. Mapping translational research in personalized therapeutics: from molecular markers to health policy
Kim et al. Depression in nonalcoholic fatty liver disease and all‐cause/cause‐specific mortality
Zang et al. Published population pharmacokinetic models of valproic acid in adult patients: A systematic review and external validation in a Chinese sample of inpatients with bipolar disorder
Gao et al. Prediction of cytochrome P450-mediated drug clearance in humans based on the measured activities of selected CYPs
Chen et al. Associations between multiple metabolic biomarkers with steatotic liver disease subcategories: A 5-year Chinese cohort study
US8073632B2 (en) Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity
Stein Does Bisphenol A (BPA) Exposure Cause Human Diseases?